Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/19071
Title: Marginal role for 53 common genetic variants in cardiovascular disease prediction
Authors: Morris, RW
Cooper, JA
Shah, T
Wong, A
Drenos, F
Engmann, J
McLachlan, S
Jefferis, B
Dale, C
Hardy, R
Kuh, D
Ben-Shlomo, Y
Wannamethee, SG
Whincup, PH
Casas, JP
Kivimaki, M
Kumari, M
Talmud, PJ
Price, JF
Dudbridge, F
Hingorani, AD
Humphries, SE
Issue Date: 30-Jun-2016
Publisher: BMJ Publishing Group
Citation: Heart, 2016, 102 (20), pp. 1640 - 1647
Abstract: Objective We investigated discrimination and calibration of cardiovascular disease (CVD) risk scores when genotypic was added to phenotypic information. The potential of genetic information for those at intermediate risk by a phenotype-based risk score was assessed. Methods Data were from seven prospective studies including 11..851 individuals initially free of CVD or diabetes, with 1444 incident CVD events over 10â..years' follow-up. We calculated a score from 53 CVD-related single nucleotide polymorphisms and an established CVD risk equation QRISK-2' comprising phenotypic measures. The area under the receiver operating characteristic curve (AUROC), detection rate for given false-positive rate (FPR) and net reclassification improvement (NRI) index were estimated for gene scores alone and in addition to the QRISK-2 CVD risk score. We also evaluated use of genetic information only for those at intermediate risk according to QRISK-2. Results The AUROC was 0.635 for QRISK-2 alone and 0.623 with addition of the gene score. The detection rate for 5% FPR improved from 11.9% to 12.0% when the gene score was added. For a 10-year CVD risk cut-off point of 10%, the NRI was 0.25% when the gene score was added to QRISK-2. Applying the genetic risk score only to those with QRISK-2 risk of 10%-<20% and prescribing statins where risk exceeded 20% suggested that genetic information could prevent one additional event for every 462 people screened. Conclusion The gene score produced minimal incremental population-wide utility over phenotypic risk prediction of CVD. Tailored prediction using genetic information for those at intermediate risk may have clinical utility.
URI: http://bura.brunel.ac.uk/handle/2438/19071
DOI: http://dx.doi.org/10.1136/heartjnl-2016-309298
ISSN: 1355-6037
http://dx.doi.org/10.1136/heartjnl-2016-309298
1468-201X
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf693.09 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.